Combined treatment with the AKT inhibitor Ipatasertib and abiraterone significantly increased progression-free survival of metastatic castration-resistant prostate cancer patients compared to abiraterone alone especially in patients with PTEN-loss tumors and activated PI3K/AKT signaling55. This evidence concerns the gene AKT1 and Familial prostate cancer.